Flatlander schreef op 8 mei 2020 04:24:
I've been out of the office for a couple days, so I'm catching up on the board and with the flood of earnings announcements. Shown below is the Cepheid part of the Danaher report. Pretty stellar growth in that POC unit.
FL
In Diagnostics, there were very strong results from Danaher's point-of-care businesses at Cepheid and Radiometer, Joyce said. Cepheid's core revenue growth increased more than 40 percent, with broad based strength across all major product lines and geographies.
Strength in Cepheid's flu assay was driven by "the combination of a more severe flu season and increased testing" during the SARS-CoV-2 outbreak, Joyce said. The company also saw early strong demand for Cepheid's SARS-CoV-2 test, which received Emergency Use Authorization from the US Food and Drug Administration at the end of March. The test returns results in 45 minutes and can run on the global installed base of 23,000 instruments, including 5,000 in the US. Joyce said the firm has shipped 2 million test cartridges so far and expects to ship 6 million per quarter.
"We are continuing to expand our capacity, but every test that we produce every single day gets shipped, and demand is continuing to build," Joyce said of Cepheid.
The increased demand for molecular point-of-care tests drove increased instrument placements globally, Joyce said. But hospital and reference labs had lower activity due to declines in wellness checks, elective procedures, ER visits, which negatively impacted test volumes.